MACULASER

Maculaser has been awarded a 400kEUR Deep Tech Accelerator grant from Business Finland. This brings our total private and public funding […]... Maculaser's pioneering retinal treatment triggers the natural healing response of senescent cells with personalized heat exposure. Targeting disease prevention, we offer a patient-specific, non-damaging solution to retinal disorders affecting millions worldwide... Rooted in pioneering research in the top biomedical engineering laboratory at Aalto University, Finland, since 2013, Maculaser aims to revolutionize retinal health care. Targeting conditions like Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Central Serous Chorioretinopathy (CSC), we strive to tackle the root causes of the diseases and make prevention a cornerstone of eye care. Our journey is advancing towards initiating our clinical trials.

Also known as: Maculaser Oy

Primary location: Helsinki Finland